Open an account

Lifecore Biomedical

LFCR · NASDAQ

$6.37−$0.02 (−0.31%)TodayMarket closed ·
Prev close $6.39

About LFCR

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 382 full-time employees. The company manufactures pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) using fermentation-based HA process. The company manufactures HA in bulk form and for use in formulated and filled syringes and vials for our customers’ injectable products used in treating medical conditions and procedures, including ophthalmic and orthopedic applications. Its product development service capabilities include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation and production of materials for clinical studies. The company also operates semi-automated restricted access barrier systems (RABS) and fully automated aseptic filling lines with isolators.

Employees
382
Headquarters
Chaska, Minnesota
Listed
Feb 15, 1996
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
lifecore.com

LFCR key statistics

Market cap
241.46M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
561.72K
Volume
588.30K
Open price
$6.38
High today
$6.40
Low today
$6.37
52 Week high
$8.98
52 Week low
$3.63

Lifecore Biomedical (LFCR) at a glance

Lifecore Biomedical (LFCR) last traded at $6.37, with a market cap of 241.46M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.37 and $6.40. The current price is 0.0% above the day's low and 0.5% below its high.

Volume so far is 588.30K shares, in line with the average of 561.72K shares a day.

Over the past year Lifecore Biomedical has ranged from $3.63 to $8.98, and now sits 51% of the way up that range.

Lifecore Biomedical met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.19 per share against an estimate of -$0.2278.

The average analyst price target is $5.75, 9.7% below the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.75
Low
$5.05
Now
$6.37
High
$6.59

LFCR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 23.4% on average.

  1. Q4 FY23: reported -$0.89 per share against an estimate of -$0.3825
  2. Q4 FY24: reported -$0.17 per share against an estimate of -$0.1224
  3. Q1 FY25: reported -$0.49 per share against an estimate of -$0.4743
  4. Q2 FY25: reported -$0.25 per share against an estimate of -$0.2958
  5. Q3 FY25: reported -$0.47 per share against an estimate of -$0.153
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0969
  7. Q1 FY26: reported -$0.43 per share against an estimate of -$0.2448
  8. Q2 FY26: reported -$0.19 per share against an estimate of -$0.2278

LFCR news

  • Press releasePRNewswire

    Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MG

  • Caroline Ryan

    Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankruptcy

  • Press releaseBusiness Wire

    Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)

  • Press releasePRNewswire

    Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.

  • Press releaseBusiness Wire

    LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders

Similar companies

Companies in the same industry as Lifecore Biomedical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.